<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792971</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4419-005</org_study_id>
    <nct_id>NCT03792971</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects</brief_title>
  <official_title>Phase 1, Open-label, One-arm, Fixed-sequence Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center, phase 1, open-label, fixed-sequence study under fasting
      conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the
      single-dose pharmacokinetic (PK) of dextromethorphan (DM) capsules liquid filled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2019</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile for dextromethorphan (DM) (in plasma): AUC0-t</measure>
    <time_frame>Pre-dose on Day 1, and at 0.5, 1 (immediately prior to the end of GC4419 infusion), 2, 3, 4, 6, 8, 12, and 24 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile for dextromethorphan (DM) (in plasma): AUC0-inf</measure>
    <time_frame>Pre-dose on Day 1, and at 0.5, 1 (immediately prior to the end of GC4419 infusion), 2, 3, 4, 6, 8, 12, and 24 hours after the start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile for dextromethorphan (DM) (in plasma): Cmax</measure>
    <time_frame>Pre-dose on Day 1, and at 0.5, 1 (immediately prior to the end of GC4419 infusion), 2, 3, 4, 6, 8, 12, and 24 hours after the start of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fixed Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan HBr</intervention_name>
    <description>A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3</description>
    <arm_group_label>Fixed Sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4419</intervention_name>
    <description>Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4</description>
    <arm_group_label>Fixed Sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, non-smoker, ≥ 18 and ≤ 55 years of age, with BMI &gt; 18.5 and &lt; 30.0
             kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.

          2. Healthy as defined by:

               1. the absence of clinically significant illness and surgery within 4 weeks prior to
                  dosing.

               2. the absence of clinically significant history of neurological, endocrinal,
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,
                  gastrointestinal, renal, hepatic, and metabolic disease.

          3. Females of childbearing potential must be willing to use acceptable contraceptive
             method throughout the study and for 30 days after the last study drug administration:

          4. Male subjects must be willing to use acceptable contraceptive method from the first
             dosing until at least 90 days after the last study drug administration:

          5. Male subjects (including men who have had vasectomies) with a pregnant partner must
             agree to use a condom from the first dosing until at least 90 days after the last
             study drug administration.

          6. Male subjects must be willing not to donate sperm until 90 days following the last
             study drug administration.

          7. Capable of consent.

          8. Consent to perform genotyping for CYP2D6.

        Exclusion Criteria:

          1. Any clinically significant abnormality at physical examination, clinically significant
             abnormal laboratory test results

          2. Positive urine drug screen or urine cotinine test at screening.

          3. History of allergic reactions to GC4419, DM, or other related drugs.

          4. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days
             prior to the first DM administration.

          5. Poor CYP2D6 metabolizers as determined by genetic testing.

          6. Positive pregnancy test at screening.

          7. Any reason which, in the opinion of the Principal Investigator, would prevent the
             subject from participating in the study.

          8. Clinically significant ECG abnormalities or vital sign abnormalities

          9. History of significant alcohol abuse within one year prior to screening or regular use
             of alcohol within six months prior to the screening visit

         10. History of significant drug abuse

         11. Participation in a clinical research study involving the administration of an
             investigational or marketed drug or device within 30 days prior to the first dosing,
             administration of a biological product in the context of a clinical research study
             within 90 days prior to the first dosing, or concomitant participation in an
             investigational study involving no drug or device administration.

         12. Use of medication other than hormonal contraceptives and topical products without
             significant systemic absorption:

         13. Donation of plasma within 7 days prior to dosing.

         14. Breast-feeding subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inventiv Health Clinical - Research Pharmacy Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

